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Abstract
Fosfomycin is a broad-spectrum antibiotic discovered in Spain in 1969. It has bactericidal activity against a wide range of bacteria, includ-
ing gram-negative micro-organisms and some gram-positive bacteria, such as staphylococci. Initially fosfomycin was administered paren-
terally and only to patients with severe infections. Today it is often dispensed as fosfomycin–trometamol, an oral formula
recommended in the treatment of urinary tract infections. Fosfomycin–trometamol in a single dose is indicated for the treatment of
women with uncomplicated urinary tract infections.
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Introduction
The increasing antimicrobial drug resistance of bacterial
pathogens, together with the relative shortage of new anti-
microbial agents, call for a new look at the therapeutic
options. One of the alternative treatments for multidrug-
resistant pathogens is fosfomycin.
Fosfomycin was ﬁrst discovered in Spain in 1969 from cul-
tures of the Streptomyces species and was originally named
‘fosfomycin’. It is currently available as a systemic antibiotic
that has no structural relationship with other known classes
of agents.
It has a broad antibacterial spectrum, targeting bacteria
with mucopeptide synthesis by inhibiting phosphoenolpyr-
uvate transferase, the ﬁrst enzyme involved in the synthesis
of peptidoglycan [1]. There is no cross-resistance, and fosfo-
mycin can be administered in combination with a number of
other antimicrobial agents.
Chemical Structure
Fosfomycin is a relatively small hydrophilic agent with negli-
gible serum protein binding. It is excreted unchanged in
urine, achieving high concentrations for a prolonged period
[2].
Fosfomycin distributes well into the tissues, achieving
clinically relevant concentrations in sites such as serum,
soft tissues, lung, bone, cerebrospinal ﬂuid and heart
valves.
Classiﬁcations
Fosfomycin belongs to the class of phosphonic antibiotics:
three phosphonic antibiotics in parenteral use are known:
fosfomycin, fosmidomycin and alafosfalin, the last of which
was abandoned. Initially, for many years fosfomycin–disodium
was administered parenterally to patients with serious infec-
tions, including meningitis [3]. More recently, it has been
produced in an oral form, fosfomycin–trometamol, which is a
monobasic hydrosoluble fosfomycin salt used speciﬁcally in
the treatment of urinary tract infections. With the exception
of fosfomycin–trometamol salt the data on the other prod-
ucts is limited [1].
In some European countries, fosfomycin–disodium is occa-
sionally administered for the treatment of patients with sep-
sis and soft-tissue infections [4].
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Despite the fact that in most European countries fosfomy-
cin–disodium has been used for many years, it has become
available for clinical use only recently for example in Turkey.
In the USA, the Food and Drug Administration has approved
fosfomycin–trometamol only for the treatment of patients
with uncomplicated cystitis [3].
The use of fosfomycin for treating multidrug-resistant bac-
terial infections and in the treatment of paediatric cancer
patients with fever and neutropenia in combinations with
other antibiotics has drawn attention to this agent [3].
Fosfomycin has a rapid bactericidal effect and a wide anti-
bacterial spectrum including methicillin-resistant Staphylococ-
cus aureus, vancomycin-resistant enterococci and a large
number of gram-negative pathogens [5–7].
Fosfomycin has the smallest molecular mass (138 Da) of
existing antibiotics, which ensures extensive diffusibility. It is
reasonably soluble in water [1] and the drug substance is
stable under normal storage conditions (2–3 years). Fosfo-
mycin is also strongly polar and hence is a very soluble
molecule. The product is unstable in an acidic medium and
so has poor oral bioavailability in the form of the disodium
salt, which is reserved for the parenteral route [1]. How-
ever, fosfomycin–trometamol is a hydrosoluble product,
which allows oral administration. After absorption, fosfomy-
cin–trometamol releases fosfomycin by hydrolysis. The
molecular weight of fosfomycin–trometamol is 259.2 Da,
and the product is presented in the form of a white crystal-
line powder.
Pharmacokinetics of Fosfomycin–
Trometamol
The concentrations in serum are higher when the compound
is administered before food intake. Pharmacokinetic parame-
ters indicate that absorption is signiﬁcantly reduced after
food intake. Fifty-eight per cent of the administered dose is
found in the urine within 24 h [7–9].
Urinary concentrations are high and may exceed 2000 mg/
L after administration of a single dose. Urinary levels remain
high for a prolonged period (over 24 h) constituting an argu-
ment in favour of its use in the treatment of common uri-
nary tract infections [10].
Mechanism of Action of FOM
Fosfomycin inhibits bacterial cell wall biosynthesis by acting
on the initial stages in the synthesis of peptidoglycan proce-
dures [11].
Antibacterial Activity
Fosfomycin is a broad-spectrum antibiotic, with moderate
activity against numerous bacterial species. Its activity depends
on its transportation into the bacterial cell by 1-a-glycero-
phosphate transport system and hexose monophosphate
systems involving the presence of glucose-6-phosphate. For
this reason the antibacterial activity of fosfomycin in vitro
requires the addition of glucose-6-phosphate to the medium
to determine MIC [1,12,13].
The antibacterial spectrum of fosfomycin includes staphylo-
cocci, Haemophilus sp. and most of the enteric gram-negative
bacteria, but with a considerably higher MIC for Klebsiella sp.,
Enterobacter sp. and Serratia sp. Fosfomycin is moderately
active against Pseudomonas aeruginosa with variable MICs rang-
ing from 4 to >512 mg/L. Acinetobacter sp. is not susceptible
to fosfomycin (MIC from 16 to 128 mg/L). Falagas et al. [6]
reported 17 antimicrobial susceptibility studies, including 5057
clinical isolates of Enterobacteriaceae, 4448 of them were
positive for extended spectrum beta-lacatamase (ESBL); 11 of
the 17 studies reported that at least 90% of the isolates were
susceptible to fosfomycin, using a MIC breakpoint of 64 mg/L
or less, 1604 (96.8%) of 1657 Escherichia coli producing ESBL
were susceptible to fosfomycin, and 608 (81.3%) of 748 Klebsi-
ella pneumoniae isolates were susceptible to fosfomycin. Fosfo-
mycin has a rapid bactericidal effect and a wide antibacterial
spectrum, including methicillin-resistant Staphylococcus aureus,
glycopeptide-susceptible and glycopeptide-resistant entero-
cocci and a large number of gram-negative pathogens.
Peak plasma levels of 22–32 mg/L occur 2–2.5 h after a
single oral dose of fosfomycin [14]. The drug is not bound
to plasma proteins. It does not undergo metabolism in the
body and is primarily excreted unchanged in the urine by
glomerular ﬁltration. Peak urinary concentrations occur
within 4 h of dosing. After a single 3-g oral dose, urine fosfo-
mycin levels >128 mg/L are maintained for at least 36–48 h.
These levels are sufﬁcient to inhibit most urinary pathogens.
It has good penetration of the kidneys, bladder wall, prostate
and seminal vesicles. Urinary fosfomycin levels are not com-
promised by mild degrees of renal insufﬁciency. Cerebrospi-
nal ﬂuid penetration is about 25%.
It has a long serum half-life and high concentrations in urine
after oral administration, so fosfomycin–trometamol deserves
further consideration for single-dose treatment of urinary tract
infections [15–17]. Fosfomycin–trometamol has c. 40% oral
bioavailability and is primarily excreted in the urine. The
substance is active against gram-positive and gram-negative bac-
teria but shows decreased activity against Morganella morganii,
Porphyromonas vulgaris, P. aeruginosa and Enterococcus faecium.
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Despite its being in use for many years, fosfomycin–tro-
metamol continues to have a low incidence of E. coli resis-
tant strains (1–3%) worldwide. Fosfomycin–trometamol has
retained its activity against quinolone-resistant strains of
E. coli and cross-resistance with other classes of antibiotics is
at present not a problem. It is less active, however, against
coagulase-negative staphylococci. The effect of fosfomycin–
trometamol on the intestinal ﬂora after the intake of a single
3-g dose has not been well established. However, because of
limited exposure the effect is probably minor.
Oteo et al. [18] showed in Spain a parallel increase in the
use of fosfomycin in the community and resistance to fosfo-
mycin in ESBL-producing E. coli.
We checked in unpublished data the susceptibility to fos-
fomycin–trometamol of 374 community-acquired uropatho-
gens in northern Israel. Susceptibility was measured by disk
sensitivity (200 mg/L). A bacterium was conﬁrmed as sensi-
tive when the inhibition zone was greater than 16 mm.
From 374 community isolates, 264 were E. coli, 44 were
K. pneumoniae and 31 were Proteus sp.
Ninety-nine per cent of the E. coli, 82% of the Klebsiella
sp. and 90% of the Proteus were sensitive to fosfomycin–tro-
metamol. However, the sensitivity was found to be lower in
Enterobacter sp. (50%) and M. morganii (17%). The 4.6% of
Enterobacteriaceae that were ESBL-producers were sensitive
to fosfomycin–trometamol .
The ARESC (Antimicrobial Resistance Epidemiological Sur-
vey on Cystitis) study group [19] collected clinical data from
4264 eligible patients. A positive urine culture was found in
74.6%, and E. coli was most frequent (76.7%) with the highest
rate of susceptibility to fosfomycin (98.1%). In all countries, a
susceptibility rate of E. coli above 90% was found only for fos-
fomycin, mecillinam and nitrofurantoin. The conclusions of the
ARESC study were that fosfomycin, mecillinam and nitrofuran-
toin have preserved their in vitro activity in all countries investi-
gated, representing good options for empiric therapy of female
patients with uncomplicated cystitis. Falagas et al. [20] pub-
lished a meta-analysis of 27 randomized controlled trials (eight
were blind) on fosfomycin versus other antibiotics for the
treatment of cystitis. The conclusion was that in an era with
high drug resistance rates, even among community-acquired
uropathogens, fosfomycin may provide a valuable alternative
option for the treatment of cystitis in women (non-pregnant
and pregnant) and in elderly and paediatric patients.
Indications
De Cueto et al. [21] present more data regarding the
susceptibility of fosfomycin–trometamol to ESBL-producing
Enterobacteriaceae. They found that from 428 ESBL-produc-
ing isolates, 417 (87.4%) were susceptible to fosfomycin–tro-
metamol (MIC £64 mg/mL). Fosfomycin shows maintained
activity against ESBL-producing strains and does not present
co-resistance with other antimicrobial groups [21].
Fosfomycin–trometamol in a 3-g single-dose can be used
to treat women, including pregnant women, with uncompli-
cated urinary tract infections.
For empiric therapy of frequent uncomplicated cystitis fos-
fomycin–trometamol together with nitrofurantoin is recom-
mended as ﬁrst-line antibiotics [22].
It has been used successfully to treat recalcitrant prostati-
tis caused by a vancomycin-resistant enterococcus in a
patient who wished to avoid intravenous therapy. In this
instance, it was administered orally once every 3 days for
3 weeks, based on the fact that therapeutic levels of the
drug are known to be present in the urine for at least 36–
48 h after a single oral dose [14]. Fosfomycin–trometamol
has not been approved in all European countries for use in
pregnant women.
In males (prostatitis): we suggest an oral 3 g every 2–
3 days for a total of 21 days, but this requires more clinical
evaluation [14,23].
Adverse Effects
Fosfomycin is very well tolerated and the adverse effects
range is in 1–10% of patients [23].
Only minor, self-limiting adverse effects were observed:
rash, headache, nausea, rhinitis, vaginitis, etc. In Japan, only
one case of pseudomembranous colitis was noted in a post-
marketing study involving 35 481 patients over a 6-year per-
iod [14].
Conclusion
Fosfomycin–trometamol could have an increased role as a
therapeutic option against multidrug-resistant community-
acquired pathogens, including those in pregnant women.
Further research is required to evaluate the potential util-
ity of the agent as a systemic antibiotic.
A panel of international experts was convened by the
Infectious Diseases Society of America (IDSA) in collabora-
tion with the European Society for Microbiology and Infec-
tious Diseases (ESCMID) to update the Clinical Practice
Guidelines for the treatment of acute uncomplicated
cystitis and pyelonephritis from 1999. They all agreed that
the optimal treatment for acute uncomplicated cystitis is
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nitrofurantoin followed by trimethoprim–sulfamethoxazole.
If the resistance rate is >20% fosfomycin is an appropriate
choice for therapy but it appears to have inferior efﬁcacy
[19,23].
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